Clinical Trial Update: Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tepotinib versus standard treatment in adults with advanced MET exon 14-mutated non-small cell lung cancer that has been previously t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tepotinib (tepotinib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation | Phase 3 | Status: RECRUITING